Andrea Schietinger is an Assistant Member in the Immunology Program at Memorial Sloan Kettering Cancer Center (MSKCC), and Assistant Professor at Weill Cornell Medical College in New York. She received her degree in Pharmacology from the University of Hamburg, Germany, before going on to do her Ph.D. with Dr. Hans Schreiber at the University of Chicago, where she studied how aberrant glycosylation of wildtype proteins in cancer cells creates tumor-specific neoantigens. As a Cancer Research Institute Irvington postdoctoral fellow in Dr. Philip Greenberg’s lab at the University of Washington in Seattle, she defined the transcriptional programs needed for self-reactive T cells to maintain self-tolerance. Since joining MSKCC in 2015, Dr. Schietinger’s laboratory studies the regulatory molecular and epigenetic mechanisms underlying T cell differentiation and dysfunction in the context of self-tolerance, autoimmunity and tumors. Dr. Schietinger is the 2017 recipient of the NIH Director’s New Innovator Award.